Genomics CEO Says Vertex R&D Pact, £25m Series B Secure Its Viability
The Oxford biotech raised £25m from investors and inked a collaboration with Vertex that's probably worth tens of millions of pounds, maybe much more. The founder and CEO of Genomics PLC tells Scrip the four-year-old company will also seek other pharma alliances.
You may also be interested in...
Third quarter device financing totaled $2.6 billion, a 24% decrease from the $3.4 billion brought in during Q2. The change partially stems from a sharp decline in debt financing. During the third quarter, debt raises brought in $258 million, just 10% of the Q3 total, while in the previous quarter, aggregate debt (at $947 million) represented 28% of the financing total.
Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.